First Trust Advisors
DYN icon

First Trust Advisors’s Dyne Therapeutics DYN Stock Holding History

First Trust Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,283
Closed -$1.16M – 2580
2024
Q3 		$1.16M Buy
32,283
+4,462
+16% +$178K ﹤0.01% 1981
2024
Q2 		$982K Buy
+27,821
New +$808K ﹤0.01% 1958
2022
Q3 		– Sell
-36,984
Closed -$254K – 2508
2022
Q2 		$254K Sell
36,984
-937
-2% -$6.46K ﹤0.01% 2338
2022
Q1 		$366K Sell
37,921
-2,201
-5% -$18.7K ﹤0.01% 2333
2021
Q4 		$477K Buy
40,122
+5,128
+15% +$72.1K ﹤0.01% 2300
2021
Q3 		$568K Buy
+34,994
New +$620K ﹤0.01% 2246

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Trust Advisors's DYN Position: Q4 2024 in Review

First Trust Advisors sold out of Dyne Therapeutics (DYN) in Q4 2024, closing a stake of 32,283 shares — an estimated $1.16M sold.

First Trust Advisors first reported a position in DYN in Q3 2021 and held it in 6 quarters. The position peaked at $1.16M in Q3 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q4 2024.

  • First Trust Advisors reported no remaining Dyne Therapeutics position as of Q4 2024 after selling out during the quarter.
  • First Trust Advisors sold 32,283 Dyne Therapeutics shares in Q4 2024, an estimated $1.16M.
  • First Trust Advisors first reported a position in Dyne Therapeutics in Q3 2021 and held it in 6 quarters.
  • First Trust Advisors's Dyne Therapeutics position peaked at $1.16M in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2024.

Based on First Trust Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.